Current Investments

Eidos Therapeutics
Minority Equity
Developing a novel therapeutic that addresses the root cause of Transthyretin (TTR) amyloidosis
Eidos Therapeutics, Inc. (NASDAQ: EIDX) is developing a novel drug to treat all forms of Transthyretin (TTR) amyloidosis, a condition characterized by toxic amyloid aggregates in the heart and peripheral nerves. The lead candidate, AG10 is an orally-administered, small molecule designed to mimic a naturally-occurring genetic rescue mutation that protects high-risk individuals from developing TTR amyloidosis.
Headquarters: San Francisco, California
Website: http://eidostx.com/
read more
Essential Medical
Minority Equity
A medical device company transforming the vascular closure market
Essential Medical is a medical technology company developing best-in-class vascular closure devices for femoral punctures following cardiac catheterization procedures. These procedures, such as TAVR and EVAR, are some of the fastest growing segments within interventional cardiology, highlighting the need for fast, easy and uncomplicated arterial closure solutions.
Headquarters: Malvern, Pennsylvania
Website: http://www.essmedclosure.com/
read more
GTx
Minority Equity
Targeted hormonal therapies to provide better medicines for patients
GTx, Inc. (NASDAQ: GTXI) is a clinical stage biotechnology company focused on developing small molecules that selectively modulate the effects of certain hormones produced by the body. The company is moving forward selective androgen receptor modulators, also referred to as SARMs, to potentially treat a number of diseases such as stress urinary incontinence.
Headquarters: Memphis, Tennessee
Website: http://www.gtxinc.com/
read more
Inspire Medical Systems
Minority Equity
A manufacturer of the first fully implantable treatment for sleep apnea
Inspire Medical Systems, Inc. (NYSE: INSP) developed the world's first fully implantable neurostimulation system for treatment of obstructive sleep apnea. The device works by opening up the upper airway in synchrony with patient's breathing during sleep through gentle stimulation of the key airway muscles. It offers a safe, effective and minimally invasive alternative to millions of patients who have failed or are intolerant of Continuous Positive Airway Pressure (CPAP).
Headquarters: Maple Grove, Minnesota
Website: https://www.inspiresleep.com/
read more
Iterum Therapeutics
Minority Equity
A clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant (MDR
Iterum Therapeutics plc (NASDAQ:ITRM) is dedicated to developing differentiated anti-infectives aimed at combatting multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound with oral and IV formulations for the treatment of uncomplicated and complicated urinary tract infection and complicated intra-abdominal infection.
Headquarters: Dublin, Ireland
Website: http://www.iterumtx.com
read more
KEW Group Inc.
Minority Equity
A personalized oncology services provider
KEW Group Inc. (KEW) is revolutionizing cancer care by empowering oncologists with access to genomic insights to design optimal, individualized treatment approaches for patients. KEW Group’s comprehensive set of products and solutions are designed to provide clarity above the complexity of genome-guided, personalized cancer therapy, arming oncologists with knowledge, informing today’s treatment decisions, and guiding tomorrow’s new therapies.
Headquarters: Cambridge, Massachusetts
Website: http://www.kewgroup.com
read more
MEI Pharma
Minority Equity
An emerging pharmaceutical company focused on advancing new therapies for cancer.
MEI Pharma, Inc. (NASDAQ: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The company’s diverse portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The clinical development pipeline also includes ME-401, a highly selective, oral PI3K delta inhibitor, voruciclib, an oral, selective CDK inhibitor, and ME-344, a novel mitochondrial inhibitor.
Headquarters: San Diego, California
Website: http://www.meipharma.com
read more
MIACH
Minority Equity
An emerging developer of bio-engineered implants for connective tissue injury.
MIACH Orthopaedics, Inc. is a medical technology company developing innovative bio-engineered surgical implants for connective tissue repair. The company’s initial focus is on the Bridge-Enhanced® ACL Repair (BEAR®) technology as a viable high performance alternative to conventional ACL reconstruction using grafts. The BEAR technology was pioneered by Martha Murray, M.D., at the Boston Children’s Hospital Department of Orthopaedic Surgery.
Headquarters: Boston, Massachusetts
Website:
read more
Selecta Biosciences, Inc.
Minority Equity
Unlocking the full potential of biologic therapies by avoiding unwanted immune responses
Selecta Biosciences, Inc. (NASDAQ: SELB) is a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta is combining its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. SEL-212, the company’s lead candidate is being developed to treat severe gout patients.
Headquarters: Watertown, Massachusetts
Website: http://selectabio.com/
read more
Teligent
Minority Equity
Developer, manufacturer, and marketer of topical, injectable, complex, and ophthalmic formulations
Teligent (NASDAQ: TLGT) engages in the formulation, development, manufacture, and packaging of topical semi-solid and liquid products for pharmaceutical, cosmeceutical, and cosmetic customers in the United States.
Headquarters: Buena, New Jersey
Website: http://www.teligent.com
read more
Zosano Pharma
Minority Equity
An emerging CNS company focused on providing rapid symptom relief to patients
Zosano Pharma (NASDAQ: ZSAN) has developed a proprietary transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications. Company’s lead program ADAM Zolmitriptan (M207) is a transdermal formulation of zolmitriptan designed to provide rapid relief of migraine symptoms in a discreet and simple manner.
Headquarters: Fremont, California
Website: http://www.zosanopharma.com/
read more